ROCK2 is overexpressed in human hepatocellular carcinoma (HCC) cells, and its inhibition induces ubiquitin-mediated degradation of Cdc25A [102], which is responsible for cell cycle progression through the S phase via CDK2/Cyclin-E activation [20]. Here, ROCK2 is linked to hepatocellular carcinoma.